naturally occurring glp-1 agonists for Weight Loss: Safe or Risky? Unlocking the multifaceted roles of
Description
This centralized litigation represents plaintiffs alleging severe side effects from Zepbound and other GLP-1 drugs
Desouza, V
DPP-4 inhibitors double the circulating concentrations of both GLP-1 and GIP
Int J Mol Sci 2023
GLP-1/GIP therapy (Tirzepatide) activates both GLP-1 and GIP receptors often delivering stronger appetite control and metabolic benefits
the overall 12-month discontinuation rate for GLP-1 agonists is estimated at 36.5%, with higher rates observed in patients with obesity alone compared to those with type 2 diabetes
